PageOverview.com
 

Websites, domains, hosts that links to shirecontent.com

Our database shows, that the website shirecontent.com is linked by a total of 27 websites.

 
Number of websites/domains displayed: 27
Results found: 27
 

Websites discovered:

PENTASA® (mesalamine) Official Web Site
http://pageoverview.com/website-report/pentasaus.com
  • Expected expiration: July 22nd in 2018
  • Creation date: July 22nd in 2003
  • Renew date: June 25th in 2017
ADHD in Children
http://pageoverview.com/website-report/vyvansekids.com
Find information on ADHD in children (6-17). See Important Safety Information & Warning About Abuse and Dependence.
  • Expected expiration: December 19th in 2017
  • Creation date: December 19th in 2007
  • Renew date: November 22nd in 2016
ONCASPAR® (pegaspargase)
http://pageoverview.com/website-report/oncaspar.com
ONCASPAR (pegaspargase) is given to patients with acute lymphoblastic leukemia (ALL) as part of a group of chemotherapy medications. ONCASPAR works by starving leukemia cells of the nutrients they need to thrive.
  • Expected expiration: October 21st in 2020
  • Creation date: October 21st in 2008
  • Renew date: September 13th in 2016
  • Google Analytics: 73262557-1
Concerned About ADHD symptoms?
http://pageoverview.com/website-report/vyvanseadult.com
What are ADHD symptoms? Do ADHD symptoms differ by settings? Talk to your doctor. See Important Safety Information & Warning about Abuse and Dependence.
  • Expected expiration: December 19th in 2017
  • Creation date: December 19th in 2007
  • Renew date: November 22nd in 2016
Shire Hematology Support| Hematology Resources & Copay Assistance
http://pageoverview.com/website-report/hematologysupport.com
Living with hemophilia or von Willebrand disease? Explore Shire Hematology Support to learn about treatment trial programs and copay assistance.
  • Expected expiration: July 8th in 2018
  • Creation date: July 8th in 2015
  • Renew date: July 4th in 2017
Treatment: ADHD & Moderate to Severe B.E.D. in Adults
http://pageoverview.com/website-report/shireregistration.com
Find information on Vyvanse® (lisdexamfetamine dimesylate). Not for weight loss. See Important Safety Info & Warning About Abuse and Dependence.
  • Expected expiration: December 11th in 2017
  • Creation date: December 11th in 2013
  • Renew date: November 17th in 2016
FIRAZYR® (icatibant injection)
http://pageoverview.com/website-report/firazyr.com
The official website of FIRAZYR® (icatibant injection) by Shire. Learn more about associated risks and benefits, including important safety information.
  • Expected expiration: November 22nd in 2018
  • Creation date: November 22nd in 2005
  • Renew date: October 30th in 2017
Treatment: ADHD & Moderate to Severe B.E.D. in Adults
http://pageoverview.com/website-report/vyvanse.com
Find information on Vyvanse® (lisdexamfetamine dimesylate). Not for weight loss. See Important Safety Info & Warning About Abuse and Dependence.
  • Expected expiration: October 24th in 2017
  • Creation date: October 24th in 2006
  • Renew date: September 27th in 2016
Registration
http://pageoverview.com/website-report/vyvansesavings.com
  • Expected expiration: June 18th in 2017
  • Creation date: June 18th in 2010
  • Renew date: May 22nd in 2016
Official HCP Site: MYDAYIS® (mixed salts of a single-entity amphetamine product)
http://pageoverview.com/website-report/mydayis-pro.com
  • Expected expiration: July 20th in 2018
  • Creation date: July 20th in 2017
  • Renew date: July 25th in 2017
ADYNOVATE® [Antihemophilic Factor (Recombinant), PEGylated] Official Site
http://pageoverview.com/website-report/adynovate.com
The official site for ADYNOVATE. Please see ADYNOVATE Detailed Important Risk Information and full Prescribing Information.
  • Expected expiration: March 10th in 2018
  • Creation date: March 10th in 2015
  • Renew date: March 6th in 2017
Vyvanse® (lisdexamfetamine dimesylate) CII - HCP Site
http://pageoverview.com/website-report/vyvansepro.com
An ADHD and moderate to severe B.E.D in adults treatment. Limitation against use for weight loss. See Important Safety Info & Boxed Warning about Abuse and Dependence.
  • Expected expiration: April 21st in 2018
  • Creation date: April 21st in 2009
  • Renew date: March 25th in 2017
Shire : un innovateur mondial dans le domaine des produits biopharmaceutiques spécialisés
http://pageoverview.com/website-report/shire.fr
Notre but est d'aider les personnes souffrant d'une maladie qui altère leur qualité de vie à mieux vivre. Découvrez nos valeurs, notre vision et nos traitements novateurs sur le site shire.com.
  • Expected expiration: January 24th in 2018
  • Creation date: January 22nd in 2013
  • Renew date: January 24th in 2017
CINRYZE® (C1 esterase inhibitor [human])
http://pageoverview.com/website-report/cinryze.com
  • Expected expiration: April 3rd in 2018
  • Creation date: April 3rd in 2007
  • Renew date: March 8th in 2017
GATTEX® (teduglutide [rDNA origin]) for Injection
http://pageoverview.com/website-report/gattex.com
GATTEX® is a prescription medicine for adults with Short Bowel Syndrome who need additional nutrition or fluids from IV feeding. See Serious Side Effects.
  • Expected expiration: January 13th in 2021
  • Creation date: January 13th in 2005
  • Renew date: May 29th in 2016
shirecontent.com
http://pageoverview.com/website-report/shirecontent.com
  • Expected expiration: September 29th in 2017
  • Creation date: September 29th in 2009
  • Renew date: September 2nd in 2016
Treatment: ADHD & Moderate to Severe B.E.D. in Adults
http://pageoverview.com/website-report/theydotherest.com
Find information on Vyvanse® (lisdexamfetamine dimesylate). Not for weight loss. See Important Safety Info & Warning About Abuse and Dependence.
  • Expected expiration: August 10th in 2017
  • Creation date: August 10th in 2011
  • Renew date: July 14th in 2016
CUVITRU Patient | Home
http://pageoverview.com/website-report/cuvitru.com
Learn about CUVITRU, a 20% subcutaneous immunoglobulin replacement therapy for primary humoral immunodeficiency (PI) in adults and children 2 years of age and older.
  • Expected expiration: November 13th in 2018
  • Creation date: November 13th in 2015
  • Renew date: November 9th in 2017
  • Google Analytics: 82959602-1
Ulcerative Colitis (UC) Treatment | Lialda® (mesalamine)
http://pageoverview.com/website-report/lialda.com
Check out Lialda for induction of remission in active mild to moderate UC and maintenance of UC remission. Read safety info including potential kidney problems.
  • Expected expiration: June 20th in 2018
  • Creation date: June 20th in 2005
  • Renew date: May 24th in 2017
Vyvanse® (lisdexamfetamine dimesylate) Copay Information
http://pageoverview.com/website-report/vyvansecopay.com
Find your copay information. See Important Safety Info & Warning regarding Potential for Abuse and Dependence.
  • Expected expiration: November 8th in 2018
  • Creation date: November 8th in 2013
  • Renew date: October 12th in 2017
Official Site for ADVATE® [Antihemophilic Factor (Recombinant)]
http://pageoverview.com/website-report/advate.com
Learn about ADVATE. Please see the ADVATE Detailed Important Risk Information and full Prescribing Information.
  • Expected expiration: June 3rd in 2024
  • Creation date: June 3rd in 2002
  • Renew date: September 1st in 2016
Vyvanse® (lisdexamfetamine dimesylate) CII for moderate to severe B.E.D. in adults & ADHD
http://pageoverview.com/website-report/shireadhd.com
Information about a treatment for ADHD and moderate to severe binge eating disorder in adults. Limitation against use for weight loss. See Important Safety Info & Boxed Warning about Abuse and Dependence.
  • Expected expiration: June 20th in 2018
  • Creation date: June 20th in 2007
  • Renew date: May 24th in 2017
Xiidra® (lifitegrast ophthalmic solution) 5% Official ECP Site
http://pageoverview.com/website-report/xiidra-ecp.com
Discover Xiidra® (lifitegrast ophthalmic solution) 5%, indicated to treat both the signs and symptoms of Dry Eye Disease. See Safety and Prescribing Info.
  • Expected expiration: May 13th in 2018
  • Creation date: May 13th in 2016
  • Renew date: April 16th in 2017
Could I Have ADHD? | ADHDAdulthood.com
http://pageoverview.com/website-report/adhdadulthood.com
Approximately 10.5 million US adults are estimated to have ADHD. Read more about ADHD symptoms, causes and treatment options here.
  • Expected expiration: January 20th in 2018
  • Creation date: January 20th in 2016
  • Renew date: December 29th in 2016
Official Site: MYDAYIS® (mixed salts of a single-entity amphetamine product)
http://pageoverview.com/website-report/mydayis.com
Learn about Mydayis, used in the treatment of ADHD in patients 13 years and older. See Safety Info & Abuse Warning. Not for use in ages 12 & younger.
  • Expected expiration: May 28th in 2018
  • Creation date: May 28th in 2014
  • Renew date: May 2nd in 2017
Treatment: ADHD & Moderate to Severe B.E.D. in Adults
http://pageoverview.com/website-report/udotherest.com
Find information on Vyvanse® (lisdexamfetamine dimesylate). Not for weight loss. See Important Safety Info & Warning About Abuse and Dependence.
  • Expected expiration: June 21st in 2017
  • Creation date: June 21st in 2011
  • Renew date: May 25th in 2016
Xiidra® (lifitegrast ophthalmic solution) 5% for Dry Eye Disease
http://pageoverview.com/website-report/xiidra.com
Discover Xiidra ®, used for the treatment of the signs and symptoms of dry eye disease. Most common side effects include eye irritation, discomfort or blurred vision when drops are applied to the eyes, and an unusual taste sensation.
  • Expected expiration: August 26th in 2017
  • Creation date: August 26th in 2013
  • Renew date: July 30th in 2016
0.0254 // 2024-05-08 20:41:32
All Rights reserved 2018 © PageOverview.com